Effect of yoga as add-on therapy in migraine (CONTAIN)
A randomized clinical trial
Citation Manager Formats
Make Comment
See Comments

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective To evaluate the effectiveness of yoga as an adjuvant to conventional medical management on clinical outcomes in patients with migraine.
Methods CONTAIN was a prospective, randomized, open-label superiority trial with blinded endpoint assessment carried out at a single tertiary care academic hospital in New Delhi, India. Patients enrolled were aged 18–50 years with a diagnosis of episodic migraine and were randomized into medical and yoga groups (1:1). Randomization was computer-generated with a variable block size and concealed. A predesigned yoga intervention was given for 3 months. Outcomes were recorded by a blinded assessor. The primary endpoint was a decrease in headache frequency, headache intensity, and Headache Impact Test (HIT)–6 score. Secondary outcomes included change in Migraine Disability Assessment (MIDAS) score, pill count, and proportion of headache free patients.
Results Between April 2017 and August 2018, 160 patients with episodic migraine were randomly assigned to medical and yoga groups. A total of 114 patients completed the trial. Baseline measures were comparable except for a higher mean headache frequency in the yoga group. Compared to medical therapy, the yoga group showed a significant mean delta value reduction in headache frequency (delta difference 3.53 [95% confidence interval 2.52–4.54]; p < 0.0001), headache intensity (1.31 [0.60–2.01]; p = 0.0004), HIT score (8.0 [4.78–11.22]; p < 0.0001), MIDAS score (7.85 [4.98–10.97]; p < 0.0001), and pill count (2.28 [1.06–3.51]; p < 0.0003).
Conclusion Yoga as an add-on therapy in migraine is superior to medical therapy alone. It may be useful to integrate a cost-effective and safe intervention like yoga into the management of migraine.
Clinicaltrials.gov identifier CTRI/2017/03/008041.
Classification of evidence This study provides Class III evidence that for patients with episodic migraine, yoga as adjuvant to medical therapy improves headache frequency, intensity, impact, and disability.
Glossary
- AIIMS=
- All India Institute of Medical Sciences;
- CGRP=
- calcitonin gene-related peptide;
- CI=
- confidence interval;
- CIMR=
- Centre for Integrated Medicine and Research;
- HIT=
- Headache Impact Test;
- ICHD-3 beta=
- International Classification of Headache Disorders, 3rd edition (beta version);
- ITT=
- intention to treat;
- MIDAS=
- Migraine Disability Assessment questionnaire;
- NO=
- nitric oxide;
- PP=
- per protocol
Footnotes
Go to Neurology.org/N for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.
Class of Evidence: NPub.org/coe
CME Course: NPub.org/cmelist
- Received May 31, 2019.
- Accepted in final form November 22, 2019.
- © 2020 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
More Online
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Erenumab in chronic migrainePatient-reported outcomes in a randomized double-blind studyRichard B. Lipton, Stewart J. Tepper, Uwe Reuter et al.Neurology, April 17, 2019 -
Articles
An international study to assess reliability of the Migraine Disability Assessment (MIDAS) scoreW.F. Stewart, R.B. Lipton, J. Whyte et al.Neurology, September 01, 1999 -
Article
Erenumab (AMG 334) in episodic migraineInterim analysis of an ongoing open-label studyMessoud Ashina, David Dodick, Peter J. Goadsby et al.Neurology, August 23, 2017 -
Articles
Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disabilityWalter F. Stewart, Richard B. Lipton, Andrew J. Dowson et al.Neurology, March 01, 2001